News Releases Keyword Search Year None202420232022202120202019201820172016 Oct-29-2021 Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results Oct-05-2021 Oncternal Therapeutics Announced Pre-Clinical Data from ONCT-534, an Androgen Receptor N-Terminal-Domain-Binding Small Molecule Degrader, Was Accepted for Virtual Poster Presentation at AACR-NCI-EORTC Virtual International Conference on Molecular Targets Oct-01-2021 Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Sep-20-2021 Oncternal Therapeutics and Celularity Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies Sep-09-2021 Oncternal Therapeutics to Participate in September Investor Conferences Sep-01-2021 Oncternal Therapeutics Rounds Out Leadership Team with Appointment of Steven Hamburger, Ph.D. as Senior Vice President, Regulatory Affairs and Quality Assurance Aug-05-2021 Oncternal Provides Business Update and Announces Second Quarter 2021 Financial Results Aug-02-2021 Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Aug-02-2021 Oncternal Therapeutics to Participate in the BTIG Virtual Biotechnology Conference Jul-29-2021 Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results Pagination First page « first Previous page ‹ previous … Page 5 Page 6 Page 7 Page 8 Current page 9 Page 10 Page 11 Page 12 Page 13 … Next page next › Last page last »